Examinant per Autoria "Luque, Melani"
Resultats per pàgina
Opcions d'ordenació
Ítem Accés Obert CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer(MDPI, 2022) Luque, Melani; Cristóbal, Ion; Sanz Álvarez, Marta; Santos, Andrea; Zazo, Sandra; Eroles, Pilar; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Madoz-Gúrpide, Juan; García-Foncillas, Jesús; Rojo, Federico
Ítem Accés Obert Expression of phosphorylated BRD4 is markedly associated with the activation status of the PP2A pathway and shows a strong prognostic value in triple negative breast cancer patients(MDPI, 2021) Sanz Álvarez, Marta; Cristóbal, Ion; Luque, Melani; Santos, Andrea; Zazo, Sandra; Madoz-Gúrpide, Juan; Caramés, Cristina; Chiang, Cheng-Ming; García-Foncillas, Jesús; Eroles, Pilar; Albanell Mestres, Joan; Rojo, Federico
Ítem Accés Obert Generation and characterization of trastuzumab/pertuzumab-resistant HER2-Positive breast cancer cell lines(MDPI, 2023) Sanz Álvarez, Marta; Luque, Melani; Morales Gallego, Miriam; Cristóbal, Ion; Ramírez Merino, Natalia; Rangel, Yamileth; Izarzugaza, Yann; Eroles, Pilar; Albanell Mestres, Joan; Madoz-Gúrpide, Juan; Rojo, Federico
Ítem Accés Obert Targeted therapy modulates the secretome of cancer-associated fibroblasts to induce resistance in HER2-positive breast cancer(MDPI, 2021) Luque, Melani; Sanz Álvarez, Marta; Santamaría, Andrea; Zazo, Sandra; Cristóbal, Ion; Fuente, Lorena de la; Mínguez, Pablo; Eroles, Pilar; Rovira Guerín, Ana; Albanell Mestres, Joan; Madoz-Gúrpide, Juan; Rojo, Federico
Ítem Accés Obert The novel oral mTORC1/2 inhibitor TAK-228 reverses trastuzumab resistance in HER2-positive breast cancer models(MDPI, 2021) Sanz Álvarez, Marta; Martín-Aparicio, Ester; Luque, Melani; Zazo, Sandra; Martínez-Useros, Javier; Eroles, Pilar; Rovira, Ana; Albanell Mestres, Joan; Madoz-Gúrpide, Juan; Rojo, Federico